Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases
Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Their lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101) is advancing through clinical development with trials for various autoimmune diseases.